Citizens JMP initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $20 price target The company is developing a next-generation, anti-VEGF candidate, TH103, that could translate to a best-in-class profile for the multi-billion dollar wet age-related macular degeneration, diabetic macular eedem, diabetic retinopathy, and retinal vein occlusion markets, the analyst tells investors in a research note. The firm says anti-VEGFs have built an over $15B market with room for improvement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS: